Rufinamide is an antiepileptic drug to treat Lennox–Gastaut syndrome, in combination with other medications. Herein, several batch and continuous process routes to rufinamide are analysed and optimised regarding their environmental impact, to finally predict a fully continuous, telescoped process route.
No takes yet. Share an insight, caveat, or question.
Ott et al. (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: